


Thereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, Washington, D.C. 20231 on this 29th day of January, 2003.

Patents, Washington, D.C. 20231 on this 29th day of January, 2003.

  
(Signature of person mailing)  
Janice Denison  
(Typed or printed name of person)

(Signature of person mailing)  
Janice Denison

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: **Martyn Frank Burslem, et al. :**

APPLICATION NO.:10/040,570

: Examiner: **Bertoglio, Valerie**

FILING DATE: 11/01/2001

: Group Art Unit: 1632

**TITLE: MODULATION OF PDE11A ACTIVITY**

Hon. Commissioner for Patents  
Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Office Action mailed October 29, 2002, Applicant submit the following remarks. The period for response to the Office Action is extended for two months to January 29, 2003. The Commissioner is hereby authorized to charge any additional fees required, or to credit any overpayment, to Deposit Account No. 1641445.

Applicants elect claim set I, drawn to genetically-modified non-human mammals with a disruption in the PDE11A gene, with traverse. Applicants note that the subject matter of claim set II, drawn to a cell with a disruption in the PDE11A gene, is highly related to the subject matter of claim set 1. A search of subject matter related to disrupting the PDE11A gene would result in hits for both cells as well as non-human mammals; such a search would not be unduly extensive or burdensome. Indeed, in keeping with Applicants' position, a brief search of issued U.S. patents related to knockout subject matter yielded several patents with claims to both knockout animals and cells (see, e.g., U.S. Pat. Nos. 6,372,958, 6,245,965, and 6,207,878).

Patent Application  
Attorney Docket No. PCS10895ANIS

Accordingly Applicants assert that there should be no restriction requirement dividing claim set I from claim set II and request that such requirement be removed to allow the election of claims 1-7 for prosecution in this application.

Date: January 29<sup>th</sup>, 2003

Respectfully submitted,

Deborah A. Martin  
Deborah A. Martin  
Attorney for Applicant(s)  
Reg. No. 44,222

Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-1821